- Title: Subtitle
- 1062eP RYZ101 (225Ac-DOTATATE) + carboplatin + etoposide + atezolizumab in treatment-naïve patients with somatostatin receptor-expressing (SSTR2+) extensive-stage small-cell lung cancer (ES-SCLC)
- Creators
- A.S. Mansfield - Mayo Clinic in FloridaE. Parent - Mayo Clinic in FloridaN. Rivera-Rodriguez - University of Puerto Rico, Medical Sciences CampusZ. Hao - Markey Cancer CenterD. Bushnell - University of IowaC. Mulvey - University of California San Francisco Medical CenterS.H. Mehr - Nebraska Cancer SpecialistsJ.W. Goldman - Santa Monica CollegeJ. Calais - University of California, Los AngelesM. Thakur - Van Andel InstituteB. Mancini - Grand Rapids Public MuseumJ.M. Rineer - Orlando HealthP. De Jong - National Eczema AssociationA. Mettias - National Eczema AssociationX. Zhao - National Eczema AssociationH.P. Soares - Huntsman Cancer Institute
- Resource Type
- Abstract
- Publication Details
- Annals of oncology, Vol.36(Supplement 4), pp.S2091-S2092
- DOI
- 10.1016/j.annonc.2025.10.773
- ISSN
- 0923-7534
- eISSN
- 1569-8041
- Publisher
- Elsevier Ltd
- Grant note
- RayzeBio
RayzeBio.
- Language
- English
- Date published
- 12/2025
- Academic Unit
- Radiology
- Record Identifier
- 9985112978402771
Abstract
1062eP RYZ101 (225Ac-DOTATATE) + carboplatin + etoposide + atezolizumab in treatment-naïve patients with somatostatin receptor-expressing (SSTR2+) extensive-stage small-cell lung cancer (ES-SCLC)
Annals of oncology, Vol.36(Supplement 4), pp.S2091-S2092
12/2025
DOI: 10.1016/j.annonc.2025.10.773
Details
Metrics
1 Record Views